Susquehanna International Group, LLP Blueprint Medicines Corp Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2025

A detailed history of Susquehanna International Group, LLP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 412,540 shares of BPMC stock, worth $52.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

412,540

Previous 136,211 202.87%

Holding current value

$52.9 Million

Previous $11.9 Million 207.35%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$86.69 - $115.63 $24 Million - $32 Million	276,329 Added 202.87%	412,540 $36.5 Million
Q4 2024 Feb 14, 2025	BUY	$82.48 - $101.39 $1.02 Million - $1.26 Million	12,394 Added 10.01%	136,211 $11.9 Million
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $5.23 Million - $7.5 Million	62,236 Added 101.06%	123,817 $11.4 Million
Q2 2024 Aug 15, 2024	SELL	$85.18 - $108.78 $5.79 Million - $7.39 Million	-67,916 Reduced 52.45%	61,581 $6.64 Million
Q1 2024 May 07, 2024	BUY	$73.17 - $99.79 $2.95 Million - $4.02 Million	40,254 Added 45.11%	129,497 $12.3 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $9.95 Million - $21 Million	-226,338 Reduced 71.72%	89,243 $8.23 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $8.33 Million - $11.7 Million	177,592 Added 128.7%	315,581 $15.8 Million
Q2 2023 Aug 11, 2023	SELL	$42.2 - $66.37 $904,894 - $1.42 Million	-21,443 Reduced 13.45%	137,989 $8.72 Million
Q1 2023 May 16, 2023	BUY	$37.97 - $50.0 $3.72 Million - $4.9 Million	98,055 Added 159.76%	159,432 $7.17 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $530,043 - $858,190	12,909 Added 26.63%	61,377 $2.69 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $847,761 - $1.32 Million	16,979 Added 53.92%	48,468 $3.19 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $1.76 Million - $2.74 Million	-39,019 Reduced 55.34%	31,489 $1.59 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $1.93 Million - $3.93 Million	35,704 Added 102.59%	70,508 $4.5 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $262,392 - $322,916	2,784 Added 8.69%	34,804 $3.73 Million
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $506,529 - $684,734	-6,255 Reduced 16.34%	32,020 $3.29 Million
Q2 2021 Aug 11, 2021	BUY	$82.78 - $101.0 $2.27 Million - $2.77 Million	27,466 Added 254.1%	38,275 $3.37 Million
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $535,551 - $639,285	-5,904 Reduced 35.33%	10,809 $1.05 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $78,728 - $106,430	-855 Reduced 4.87%	16,713 $1.87 Million
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $1.4 Million - $1.96 Million	-21,125 Reduced 54.6%	17,568 $1.63 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $10.9 Million - $15.1 Million	-190,367 Reduced 83.11%	38,693 $3.02 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $8.11 Million - $13.9 Million	168,578 Added 278.72%	229,060 $13.4 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $1.79 Million - $2.22 Million	26,867 Added 79.93%	60,482 $4.85 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $100,747 - $140,148	1,382 Added 4.29%	33,615 $2.47 Million
Q2 2019 Aug 16, 2019	BUY	$73.54 - $97.8 $1.76 Million - $2.34 Million	23,915 Added 287.51%	32,233 $3.04 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $4.21 Million - $7.48 Million	-86,397 Reduced 91.22%	8,318 $666,000
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $4.68 Million - $7.77 Million	76,749 Added 427.19%	94,715 $6.01 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $1.13 Million - $1.59 Million	17,966	17,966 $1.36 Million

Others Institutions Holding BPMC

# of Institutions

391

Shares Held

68.5M

Call Options Held

1.54M

Put Options Held

1.08M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.66B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Blueprint Medicines Corp Transaction History